RxDoctor Payments Data

Michael Isaacson, MD

Urology · Rockville, MDNPI 1225262314

Payments from drug & device makers

$7,821in general payments, 2019–2025

Across 305 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$915
  • AbbVie$834
  • Astellas Pharma US Inc$598
  • Sumitomo Pharma America, Inc.$574
  • Progenics Pharmaceuticals, Inc.$466
  • Endo Pharmaceuticals Inc.$413
  • plus $4K from 39 others

What the payments were for

  • Speaking & faculty fees$1121%
  • Food & beverage$7,62197%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,821 in reported general payments places this provider in the 60th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$858,772
Medicare patients
948
Services billed
7,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron162$183,795
GemtesaVibegron43$41,644
Tamsulosin Hcl602$12,620
Alfuzosin Hcl ErAlfuzosin Hcl415$12,113
Potassium Citrate ErPotassium Citrate69$8,683
Silodosin69$8,067
Testosterone38$7,272
Dutasteride179$6,754
Mirabegron ErMirabegron14$6,146
Finasteride381$5,609
Solifenacin Succinate73$3,969
Darifenacin ErDarifenacin Hydrobromide16$3,451
Tadalafil32$3,267
Trospium Chloride24$3,106
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl14$2,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$598$183,795162 claims
Sumitomo Pharma America, Inc.Gemtesa$574$41,64443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 274 urology providers in Maryland.

Other urology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →